VistaGen Therapeutics Stock Forecast - Simple Moving Average
| VTGN Stock | USD 0.62 0.03 4.62% |
VistaGen Stock outlook is based on your current time horizon. Although VistaGen Therapeutics' naive historical forecasting may sometimes provide an important future outlook for the firm, we recommend always cross-verifying it against solid analysis of VistaGen Therapeutics' systematic risk associated with finding meaningful patterns of VistaGen Therapeutics fundamentals over time.
As of today, the RSI of VistaGen Therapeutics' share price is approaching 30. This entails that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling VistaGen Therapeutics, making its price go up or down. Momentum 30
Sell Stretched
Oversold | Overbought |
EPS Estimate Next Quarter (0.32) | EPS Estimate Current Year (1.83) | EPS Estimate Next Year (1.23) | Wall Street Target Price 0.9667 | EPS Estimate Current Quarter (0.44) |
Using VistaGen Therapeutics hype-based prediction, you can estimate the value of VistaGen Therapeutics from the perspective of VistaGen Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards VistaGen Therapeutics using VistaGen Therapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards VistaGen using crowd psychology based on the activity and movement of VistaGen Therapeutics' stock price.
VistaGen Therapeutics Short Interest
An investor who is long VistaGen Therapeutics may also wish to track short interest. As short interest increases, investors should be becoming more worried about VistaGen Therapeutics and may potentially protect profits, hedge VistaGen Therapeutics with its derivative instruments, or be ready for some potential downside.
200 Day MA 2.8097 | Short Percent 0.1224 | Short Ratio 0.59 | Shares Short Prior Month 1.8 M | 50 Day MA 2.5072 |
VistaGen Relative Strength Index
The Simple Moving Average forecasted value of VistaGen Therapeutics on the next trading day is expected to be 0.62 with a mean absolute deviation of 0.22 and the sum of the absolute errors of 13.18.VistaGen Therapeutics Hype to Price Pattern
Investor biases related to VistaGen Therapeutics' public news can be used to forecast risks associated with an investment in VistaGen. The trend in average sentiment can be used to explain how an investor holding VistaGen can time the market purely based on public headlines and social activities around VistaGen Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of VistaGen Therapeutics' market sentiment to its price can help taders to make decisions based on the overall investors consensus about VistaGen Therapeutics.
VistaGen Therapeutics Implied Volatility | 1.56 |
VistaGen Therapeutics' implied volatility exposes the market's sentiment of VistaGen Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if VistaGen Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that VistaGen Therapeutics stock will not fluctuate a lot when VistaGen Therapeutics' options are near their expiration.
The Simple Moving Average forecasted value of VistaGen Therapeutics on the next trading day is expected to be 0.62 with a mean absolute deviation of 0.22 and the sum of the absolute errors of 13.18. VistaGen Therapeutics after-hype prediction price | USD 0.62 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of VistaGen Therapeutics to cross-verify your projections. Open Interest Against 2026-03-20 VistaGen Option Contracts
Although open interest is a measure utilized in the options markets, it could be used to forecast VistaGen Therapeutics' spot prices because the number of available contracts in the market changes daily, and new contracts can be created or liquidated at will. Since open interest in VistaGen Therapeutics' options reflects these daily shifts, investors could use the patterns of these changes to develop long and short-term trading strategies for VistaGen Therapeutics stock based on available contracts left at the end of a trading day.
Please note that to derive more accurate forecasting about market movement from the current VistaGen Therapeutics' open interest, investors have to compare it to VistaGen Therapeutics' spot prices. As Ford's stock price increases, high open interest indicates that money is entering the market, and the market is strongly bullish. Conversely, if the price of VistaGen Therapeutics is decreasing and there is high open interest, that is a sign that the bearish trend will continue, and investors may react by taking short positions in VistaGen. So, decreasing or low open interest during a bull market indicates that investors are becoming uncertain of the depth of the bullish trend, and a reversal in sentiment will likely follow.
VistaGen Therapeutics Additional Predictive Modules
Most predictive techniques to examine VistaGen price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for VistaGen using various technical indicators. When you analyze VistaGen charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
VistaGen Therapeutics Simple Moving Average Price Forecast For the 28th of January
Given 90 days horizon, the Simple Moving Average forecasted value of VistaGen Therapeutics on the next trading day is expected to be 0.62 with a mean absolute deviation of 0.22, mean absolute percentage error of 0.33, and the sum of the absolute errors of 13.18.Please note that although there have been many attempts to predict VistaGen Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that VistaGen Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
VistaGen Therapeutics Stock Forecast Pattern
| Backtest VistaGen Therapeutics | VistaGen Therapeutics Price Prediction | Buy or Sell Advice |
VistaGen Therapeutics Forecasted Value
In the context of forecasting VistaGen Therapeutics' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. VistaGen Therapeutics' downside and upside margins for the forecasting period are 0.01 and 12.59, respectively. We have considered VistaGen Therapeutics' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Moving Average forecasting method's relative quality and the estimations of the prediction error of VistaGen Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent VistaGen Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 113.3156 |
| Bias | Arithmetic mean of the errors | 0.0814 |
| MAD | Mean absolute deviation | 0.2234 |
| MAPE | Mean absolute percentage error | 0.1559 |
| SAE | Sum of the absolute errors | 13.18 |
Predictive Modules for VistaGen Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as VistaGen Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.VistaGen Therapeutics After-Hype Price Density Analysis
As far as predicting the price of VistaGen Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in VistaGen Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of VistaGen Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
VistaGen Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting VistaGen Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on VistaGen Therapeutics' historical news coverage. VistaGen Therapeutics' after-hype downside and upside margins for the prediction period are 0.03 and 12.49, respectively. We have considered VistaGen Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
VistaGen Therapeutics is out of control at this time. Analysis and calculation of next after-hype price of VistaGen Therapeutics is based on 3 months time horizon.
VistaGen Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as VistaGen Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading VistaGen Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with VistaGen Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
1.54 | 11.97 | 0.02 | 0.29 | 6 Events / Month | 5 Events / Month | In about 6 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.62 | 0.62 | 0.00 |
|
VistaGen Therapeutics Hype Timeline
VistaGen Therapeutics is at this time traded for 0.62. The entity has historical hype elasticity of -0.02, and average elasticity to hype of competition of -0.29. VistaGen is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is at this time at -1.54%. %. The volatility of related hype on VistaGen Therapeutics is about 6401.07%, with the expected price after the next announcement by competition of 0.33. About 58.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.38. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. VistaGen Therapeutics recorded a loss per share of 1.92. The entity had not issued any dividends in recent years. The firm had 1:30 split on the 7th of June 2023. Given the investment horizon of 90 days the next forecasted press release will be in about 6 days. Check out Historical Fundamental Analysis of VistaGen Therapeutics to cross-verify your projections.VistaGen Therapeutics Related Hype Analysis
Having access to credible news sources related to VistaGen Therapeutics' direct competition is more important than ever and may enhance your ability to predict VistaGen Therapeutics' future price movements. Getting to know how VistaGen Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how VistaGen Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| SPRO | Spero Therapeutics | (0.04) | 9 per month | 2.67 | 0 | 3.64 | (5.04) | 13.07 | |
| SEER | Seer Inc | 0.01 | 8 per month | 0.00 | (0.12) | 3.41 | (3.06) | 9.98 | |
| MCRB | Seres Therapeutics | (1.12) | 9 per month | 0.00 | (0.02) | 9.13 | (7.64) | 54.10 | |
| IRD | Opus Genetics | 0.01 | 10 per month | 3.57 | 0.09 | 6.70 | (6.10) | 26.50 | |
| CGTX | Cognition Therapeutics | (0.05) | 2 per month | 0.00 | (0.07) | 8.89 | (8.38) | 24.96 | |
| HURA | TuHURA Biosciences | (0.05) | 12 per month | 0.00 | (0.24) | 7.73 | (10.53) | 50.34 | |
| AGEN | Agenus Inc | 0.11 | 9 per month | 0.00 | (0.11) | 6.63 | (6.79) | 30.06 | |
| ACTU | Actuate Therapeutics Common | (0.61) | 5 per month | 0.00 | (0.12) | 5.40 | (6.74) | 20.01 | |
| ABOS | Acumen Pharmaceuticals | 0.04 | 8 per month | 4.54 | 0.02 | 9.94 | (7.18) | 25.06 | |
| INO | Inovio Pharmaceuticals | (0.17) | 9 per month | 0.00 | (0.11) | 6.87 | (6.80) | 36.52 |
Other Forecasting Options for VistaGen Therapeutics
For every potential investor in VistaGen, whether a beginner or expert, VistaGen Therapeutics' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. VistaGen Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in VistaGen. Basic forecasting techniques help filter out the noise by identifying VistaGen Therapeutics' price trends.VistaGen Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with VistaGen Therapeutics stock to make a market-neutral strategy. Peer analysis of VistaGen Therapeutics could also be used in its relative valuation, which is a method of valuing VistaGen Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
VistaGen Therapeutics Market Strength Events
Market strength indicators help investors to evaluate how VistaGen Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading VistaGen Therapeutics shares will generate the highest return on investment. By undertsting and applying VistaGen Therapeutics stock market strength indicators, traders can identify VistaGen Therapeutics entry and exit signals to maximize returns.
| Rate Of Daily Change | 0.95 | |||
| Day Median Price | 0.62 | |||
| Day Typical Price | 0.62 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.03) | |||
| Relative Strength Index | 30.91 |
VistaGen Therapeutics Risk Indicators
The analysis of VistaGen Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in VistaGen Therapeutics' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting vistagen stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 5.51 | |||
| Standard Deviation | 11.44 | |||
| Variance | 130.76 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for VistaGen Therapeutics
The number of cover stories for VistaGen Therapeutics depends on current market conditions and VistaGen Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that VistaGen Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about VistaGen Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
VistaGen Therapeutics Short Properties
VistaGen Therapeutics' future price predictability will typically decrease when VistaGen Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of VistaGen Therapeutics often depends not only on the future outlook of the potential VistaGen Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. VistaGen Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 30.7 M | |
| Cash And Short Term Investments | 80.5 M |
Check out Historical Fundamental Analysis of VistaGen Therapeutics to cross-verify your projections. To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VistaGen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.92) | Revenue Per Share | Quarterly Revenue Growth 0.41 | Return On Assets | Return On Equity |
The market value of VistaGen Therapeutics is measured differently than its book value, which is the value of VistaGen that is recorded on the company's balance sheet. Investors also form their own opinion of VistaGen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VistaGen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VistaGen Therapeutics' market value can be influenced by many factors that don't directly affect VistaGen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VistaGen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.